Susquehanna International Group, LLP Amicus Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Put Options

28 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$9.55 - $12.09 $932,080 - $1.18 Million	97,600 Added 83.63%	214,300 $2.29 Million
Q2 2024 Aug 15, 2024	BUY	$9.04 - $11.75 $473,695 - $615,700	52,400 Added 81.49%	116,700 $1.16 Million
Q1 2024 May 07, 2024	SELL	$11.43 - $14.24 $880,110 - $1.1 Million	-77,000 Reduced 54.49%	64,300 $757,000
Q4 2023 Feb 14, 2024	BUY	$9.97 - $14.52 $813,552 - $1.18 Million	81,600 Added 136.68%	141,300 $2.01 Million
Q3 2023 Nov 14, 2023	BUY	$11.78 - $13.86 $228,532 - $268,884	19,400 Added 48.14%	59,700 $725,000
Q2 2023 Aug 11, 2023	BUY	$10.72 - $13.3 $432,016 - $535,990	40,300 New	40,300 $506,000
Q4 2022 Feb 14, 2023	SELL	$9.89 - $12.7 $451,973 - $580,390	-45,700 Reduced 25.85%	131,100 $1.6 Million
Q3 2022 Nov 14, 2022	BUY	$9.82 - $12.75 $1.63 Million - $2.11 Million	165,800 Added 1507.27%	176,800 $1.85 Million
Q2 2022 Aug 15, 2022	SELL	$6.23 - $11.12 $8,099 - $14,455	-1,300 Reduced 10.57%	11,000 $118,000
Q1 2022 May 16, 2022	SELL	$7.89 - $12.48 $18,936 - $29,952	-2,400 Reduced 16.33%	12,300 $116,000
Q4 2021 Feb 14, 2022	SELL	$9.82 - $12.44 $968,252 - $1.23 Million	-98,600 Reduced 87.03%	14,700 $170,000
Q3 2021 Nov 15, 2021	BUY	$8.74 - $11.84 $579,462 - $784,992	66,300 Added 141.06%	113,300 $1.08 Million
Q2 2021 Aug 11, 2021	SELL	$8.71 - $10.72 $1.86 Million - $2.3 Million	-214,100 Reduced 82.0%	47,000 $453,000
Q1 2021 May 17, 2021	BUY	$9.2 - $23.86 $1.6 Million - $4.15 Million	174,000 Added 199.77%	261,100 $2.58 Million
Q4 2020 Feb 16, 2021	BUY	$13.47 - $24.89 $421,611 - $779,057	31,300 Added 56.09%	87,100 $2.01 Million
Q3 2020 Nov 16, 2020	SELL	$12.89 - $15.89 $190,772 - $235,172	-14,800 Reduced 20.96%	55,800 $788,000
Q2 2020 Aug 14, 2020	SELL	$8.86 - $15.69 $83,284 - $147,486	-9,400 Reduced 11.75%	70,600 $1.07 Million
Q1 2020 May 15, 2020	BUY	$6.63 - $11.16 $158,457 - $266,724	23,900 Added 42.6%	80,000 $739,000
Q4 2019 Feb 14, 2020	SELL	$7.48 - $10.75 $68,068 - $97,825	-9,100 Reduced 13.96%	56,100 $546,000
Q3 2019 Nov 14, 2019	SELL	$8.02 - $13.25 $1.29 Million - $2.13 Million	-160,400 Reduced 71.1%	65,200 $523,000
Q2 2019 Aug 14, 2019	SELL	$10.96 - $14.4 $2.58 Million - $3.39 Million	-235,300 Reduced 51.05%	225,600 $2.82 Million
Q1 2019 May 15, 2019	BUY	$10.04 - $13.92 $3.63 Million - $5.04 Million	361,900 Added 365.56%	460,900 $6.27 Million
Q4 2018 Feb 14, 2019	SELL	$8.38 - $13.44 $1.12 Million - $1.8 Million	-134,100 Reduced 57.53%	99,000 $948,000
Q3 2018 Nov 14, 2018	SELL	$11.6 - $16.54 $766,760 - $1.09 Million	-66,100 Reduced 22.09%	233,100 $2.82 Million
Q2 2018 Aug 14, 2018	SELL	$13.13 - $17.09 $22.8 Million - $29.6 Million	-1,734,000 Reduced 85.28%	299,200 $4.67 Million
Q1 2018 May 15, 2018	BUY	$13.76 - $17.12 $7.76 Million - $9.65 Million	563,800 Added 38.37%	2,033,200 $30.6 Million
Q4 2017 Feb 14, 2018	SELL	$12.51 - $16.24 $869,445 - $1.13 Million	-69,500 Reduced 4.52%	1,469,400 $21.1 Million
Q3 2017 Nov 14, 2017	BUY	$11.74 - $15.78 $18.1 Million - $24.3 Million	1,538,900	1,538,900 $23.2 Million

Others Institutions Holding FOLD

# of Institutions

312

Shares Held

314M

Call Options Held

516K

Put Options Held

833K

Vanguard Group Inc Valley Forge, PA

28.8M
Shares

$271 Million
0.01% of portfolio
Perceptive Advisors LLC New York, NY

28.1M
Shares

$264 Million
7.83% of portfolio
Black Rock Inc. New York, NY

24.4M
Shares

$230 Million
0.01% of portfolio
Wellington Management Group LLP Boston, MA

24M
Shares

$226 Million
0.05% of portfolio
Avoro Capital Advisors LLC New York, NY

23.2M
Shares

$218 Million
3.72% of portfolio

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.64B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account